List of Giazo drug patents
Giazo is owned by Valeant Pharms Intl.
Giazo contains Balsalazide Disodium.
Giazo has a total of 4 drug patents out of which 0 drug patents have expired.
Giazo was authorised for market use on 03 February, 2012.
Giazo is available in tablet;oral dosage forms.
Giazo can be used as treatment of mildly to moderately active ulcerative colitis in male patients.
The generics of Giazo are possible to be released after 23 June, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192616 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
| US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
| US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
| US8497256 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males |
Jun, 2031
(8 years from now) | |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 03 February, 2012
Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic